Identification of active main metabolites of anti-infective inhibitors of the macrophage infectivity potentiator protein by liquid chromatography using mass detection.
Theresa LohrNicolas Julian ScheupleinChristopher JenkinsIsobel NorvilleChristine ErkMaximilian StapfLukas KirchnerMitali Sarkar-TysonGerhard BringmannPublished in: Archiv der Pharmazie (2024)
Due to increasing antibiotic resistance, the development of anti-infectives with new mechanisms of action is crucial. Virulence factors such as the "macrophage infectivity potentiator" (Mip) protein, which catalyzes the folding of proline-containing proteins by means of their cis-trans isomerase (PPIase) activity, have come into focus as a potential new target. Since the inhibition of Mip by small molecules has been shown to lead to reduced virulence and survival in vitro, especially of Gram-negative bacteria such as Burkholderia pseudomallei (Bp), Neisseria meningitidis (Nm), and Neisseria gonorrhoeae (Ng), or Coxiella burnetii (Cb), among many others, a library of Mip inhibitors was developed. As drug metabolism has a significant impact on the overall therapeutic outcome, this report describes the biotransformation of the most potent Mip inhibitors. Therefore, the anti-infectives were treated using human liver microsomes in vitro. Liquid chromatography with tandem mass spectrometry (LC/MS-MS) methods were applied to identify the metabolites and quantify the metabolic degradation of the hit compounds. Active metabolites, N-oxides, were found, leading to new opportunities for further drug development.
Keyphrases
- liquid chromatography
- tandem mass spectrometry
- ultra high performance liquid chromatography
- mass spectrometry
- high resolution mass spectrometry
- high performance liquid chromatography
- ms ms
- simultaneous determination
- gas chromatography
- pseudomonas aeruginosa
- escherichia coli
- staphylococcus aureus
- solid phase extraction
- adipose tissue
- antimicrobial resistance
- amino acid
- photodynamic therapy
- emergency department
- adverse drug
- risk assessment
- binding protein